Seeking investment & partnership
Dr Paul Rodgers of Psynova Neurotech explained that the company needed “£5 million over the next year to be used for R&D purposes,” adding that they are also “looking for R&D partners to help develop our biomarkers.”
The company is interested in partnership with diagnostic companies wanting to develop clinical and research assays for the biomarkers and pharmaceutical companies looking for new tools to enhance clinical development of neuropsychiatric drugs, among others.
Psynova Neurotech was established in 2005 by Dr Sabine Bahn MD, Ph.D, MRCPsych, and Professor Chris Lowe PhD. The company is currently funded by Porton Capital and the Cambridge Enterprise Seed Funds. It commercially exploits biomarkers in the treatment of schizophrenia and bipolar disorder, developing clinical diagnostics, novel therapeutics and tests for monitoring patient response to medication. The company continues to work closely with its academic partners, the Cambridge Centre for Neuropsychiatric Research (CCNR) and the Institute of Biotechnology (IOB).
Schizophrenia and bipolar disorder affect at least 2% of the population worldwide. Currently treatment can only offer relief for the symptoms rather than tackling the underlying causes due to a lack of understanding. Psynova Neurotech intends to address this knowledge gap. The company also plans to expand its work to research other illnesses such as depression, neurodegenerative disorders and substance abuse, as well as sleep and eating disorders, where it has relevant expertise.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
